|
| Press Releases |
|
 |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱重工、NEDO懸賞金活用型プログラム「GENIAC-PRIZE」で第2位を受賞
Apr 8, 2026 11:30: JST
|
|
|
三菱重工グループのCrystal Mover Services、米国アトランタ国際空港のAPMシステム「ATL SkyTrain」の設備更新工事を受注
Apr 8, 2026 11:30: JST
|
|
|
U.S. Polo Assn. and ESPN Champion the Iconic USPA Gold Cup at the USPA National Polo Center, Hosted by Legendary Commentator Chris Fowler
Apr 8, 2026 09:24 HKT/SGT
|
|
|
首程控股（0697.HK）分紅回購並舉 8年累計回饋股東約68.77億港元
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Shoucheng Holdings (0697.HK) Combines Dividends and Share Buybacks in Tandem, Returning Approximately HK$6.877 Billion to Shareholders Over Eight Years
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Formerra宣佈全球提價
Apr 8, 2026 04:00 HKT/SGT
|
|
|
Formerra宣布全球提价
Apr 8, 2026 04:00 HKT/SGT
|
|
|
Formerra Announces Global Price Increase
Apr 8, 2026 04:00 HKT/SGT
|
|
|
U.S. Polo Assn. and ESPN Champion the Iconic USPA Gold Cup at the USPA National Polo Center, Hosted by Legendary Commentator Chris Fowler
Apr 7, 2026 20:00: JST
|
|
|
美國馬球協會（USPA）與ESPN攜手呈現標誌性的USPA金杯賽，賽事將在USPA國家馬球中心舉行，由傳奇解說員克裡斯·福勒擔任主持
Apr 7, 2026 19:00 HKT/SGT
|
|
|
美国马球协会（USPA）与ESPN携手呈现标志性的USPA金杯赛，赛事将在USPA国家马球中心举行，由传奇解说员克里斯·福勒担任主持
Apr 7, 2026 19:00 HKT/SGT
|
|
|
Dwbrobot Launches Zero-Investment Robot Model to Accelerate Industrial Automation
Apr 7, 2026 18:00: JST
|
|
|
Dwbrobot Launches Zero-Investment Robot Model to Accelerate Industrial Automation
Apr 7, 2026 16:30 HKT/SGT
|
|
|
MHI Receives Contract for Renewal of APM System ATL SkyTrain at Hartsfield-Jackson Atlanta International Airport
Apr 7, 2026 16:42 JST
|
|
|
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush x Zurich 2026
Apr 7, 2026 11:06 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
